bioAffinity Prices $4M At-the-Market Private Placement, Adding 8.5M Shares
BIAF is trading near its 52-week low of $0.457 (2.6% above the low) on light trading volume (0.1× avg).
Summary
bioAffinity Technologies announced a $4 million private placement priced at-the-market under Nasdaq rules, selling 8,462,027 shares (or pre-funded warrants) plus warrants for up to 16,924,054 additional shares at a combined effective price of $0.4727 per share. The offering is expected to close August 14, 2026. This follows a $3.2 million public offering closed in June and comes as the stock trades near its 52-week low of $0.4573, with a market cap under $4 million. The at-the-market pricing avoids a discount but the warrant overhang and share count increase are dilutive. Proceeds will likely fund ongoing commercialization of CyPath Lung, which reported 216% volume growth in Q2 but widening net losses. Watch for stockholder approval of warrant exercise and any subsequent registration statement for resale.
At the time of this announcement, BIAF was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.46 to $13.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.